The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Tafasitamab, lenalidomide, and R-CHOP in frontline high-risk DLBCL: the Phase III frontMIND trial
Georg Lenz, MD, University of Münster, Münster, Germany, discusses the results of the Phase III frontMIND trial (NCT04824092), which compared the safety and efficacy of tafasitamab plus lenalidomide and R-CHOP versus R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL). Prof. Lenz highlights that the tafasitamab-containing combination therapy showed improved progression-free and overall survival, as well as higher rates of measurable residual disease (MRD) negativity, and notes that the next steps will involve identifying the specific patient subtypes that will benefit most from this therapeutic approach. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
